{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.18","value":"0.3"}]}],"title":"Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.13","value":"1.1"}]}],"title":"Day 8"}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"}],"units":"Participants"}],"description":"Clast is defined as the Last observed (quantifiable) plasma concentration (Clast), in units of ng/mL. Blood samples were collected to assess Clast.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received panobinostat 20 mg orally OD, three times a week on days: 1, 3 and 5, then 8, 10 and 12, then 15, 17 and 19 of each cycle, as part of a 3-week (21 days) treatment cycle. Participants could continue treatment until disease progression or unacceptable toxicity.","id":"OG000","title":"Panobinostat"}],"paramType":"MEAN","populationDescription":"The analysis was performed in PAS population, defined as all participants who provide at least one post-dose PK plasma sample. Here, number of participants analyzed refer to the number of participants evaluable for this outcome at specified time point.","reportingStatus":"POSTED","timeFrame":"Pre-dose, 0.25, 1-2, and 3-4 hours post dose on Day 1 and Day 8","title":"Last Observed Plasma Concentration (Clast) of Panobinostat","type":"SECONDARY","unitOfMeasure":"ng/mL"}